Melissa Kelley, Ph.D., R&D Manager, GE Healthcare Dharmacon, Inc.
GE Dharmacon has revolutionised the field of RNA synthesis with the introduction of 2’- ACE synthesis chemistry. As leaders in custom RNA synthesis, GE Dharmacon was an early participant in the field of RNA interference, and contributed several key scientific findings. This leadership has continued through technical advances in bioinformatics and chemical modifications to improve performance.
Dharmacon RNAi products now encompass the most complete portfolio of innovative tools for transient, long-term, inducible and in vivo RNAi applications. Our RNAi reagents are complemented with a complete suite of products for delivery, control and confirmation of results.
This information session will highlight some of the latest advances in RNAi tools as well as how Dharmacon is leveraging its RNA synthesis leadership to deliver innovative Dharmacon Edit-R™ CRISPR-Cas9 gene editing products that greatly simplify the workflow of permanently knocking out genes by eliminating the time-consuming cloning of individual guide RNA expression vectors.
Melissa Kelley, PhD is a Senior Scientist at Dharmacon, where she has developed and patented vector-based RNAi gene modulation products. Currently, Dr Kelley is directing multiple R&D projects focusing on the development of RNAi and CRISPR-Cas9 systems and experimental workflows utilizing these research tools.